MedTrace Logo

CoreValve™ Evolut R™ 34 mm System Registry (CoreValve34)

NCT03621709 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-03-19

No results posted yet for this study

Summary

With the introduction of the CoreValve™ Evolut R™ 34mm (Medtronic™) prosthesis, patients with severe symptomatic aortic stenosis (AS) and large aortic annulus have become eligible for transcatheter aortic valve implantation (TAVI). The aim of this study is to detect the number of TAVI candidates with large aortic annulus, and to evaluate the feasibility, efficacy, and safety of TAVI using the CoreValve™ Evolut R™ 34mm.

Conditions

  • Aortic Valve Stenosis
  • Transcatheter Aortic Valve Implantation

Sponsors & Collaborators

  • Fundacin Biomedica Galicia Sur

    lead OTHER

Principal Investigators

  • Victor A Jiménez Díaz, MD, MPH · Hospital Álvaro Cunqueiro

  • Pablo Jiménez Díaz, MD, MPH · Hospital Álvaro Cunqueiro

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2020-07-31
Completion
2020-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03621709 on ClinicalTrials.gov